Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

403
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
403

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venous Nanoflap Oscillations: Biomechanical Determinants and Hydrodynamic Consequences in the Deep Cerebral Venous System.

International journal of molecular sciences·2026
Same author

Colonic Stenting as a Bridge to Surgery Versus Emergency Resection in Obstructive Colon Cancer: A Systematic Review of Surgical Outcomes.

Journal of clinical medicine·2026
Same author

Black Sea-Derived Biomaterials for Wound-Healing Applications.

International journal of molecular sciences·2026
Same author

Spontaneous Resolution of a Bilateral Barrow Type D Indirect Carotid-Cavernous Fistula: A Rare Case Report and Literature Review.

Diagnostics (Basel, Switzerland)·2026
Same author

Clinical and inflammatory biomarkers predicting emergency surgical management decisions and postoperative outcomes in complicated colon cancer.

Journal of medicine and life·2026
Same author

Surgical Decision-Making in Breast Cancer: A Retrospective Comparative Study from a Tertiary Center.

Journal of clinical medicine·2026
Same journal

RETRACTED: Zito Marino et al. AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1993.

Journal of personalized medicine·2026
Same journal

Correction: Rao et al. Ensemble Deep-Learning-Based Prognostic and Prediction for Recurrence of Sporadic Odontogenic Keratocysts on Hematoxylin and Eosin Stained Pathological Images of Incisional Biopsies. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1220.

Journal of personalized medicine·2026
Same journal

Three-Dimensional Bronchovascular Modelling in Sublobar Pulmonary Resection: A Tool for Personalised Thoracic Surgery.

Journal of personalized medicine·2026
Same journal

Serum Albumin, Globulin and Albumin-Globulin Ratios as Biomarkers of Clinical Outcomes in COVID-19 Pneumonia.

Journal of personalized medicine·2026
Same journal

New Advances and Perspectives in Ophthalmology: Progress and Modern Challenges Toward Personalized Eye Care.

Journal of personalized medicine·2026
Same journal

Bridging Ancestry-Stratified Bias in Pharmacogenomics AI: Toward Metabolomics-Inclusive Multi-Omics Precision Medicine.

Journal of personalized medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.0K

Complement Inhibitors for Geographic Atrophy in Age-Related Macular Degeneration-A Systematic Review.

Ana Maria Dascalu1,2, Catalin Cicerone Grigorescu3, Dragos Serban1,4

  • 1Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Journal of Personalized Medicine
|September 28, 2024
PubMed
Summary
This summary is machine-generated.

Intravitreal complement inhibitors show promise for treating geographic atrophy (GA) in age-related macular degeneration (AMD). While not improving vision, they slightly slowed GA progression compared to controls, with manageable side effects.

Keywords:
age-related macular degenerationavacincaptad pegolbiomarkerscomplement inhibitorsgeographic atrophylampalizumaboutcomespegcetacoplanpersonalized therapy

More Related Videos

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.1K
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.1K

Related Experiment Videos

Last Updated: Jun 11, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.0K
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.1K
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.1K

Area of Science:

  • Ophthalmology
  • Regenerative Medicine
  • Pharmacology

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss globally.
  • Geographic atrophy (GA) is an advanced form of AMD.
  • Intravitreal complement inhibitors are a novel therapeutic class for AMD.

Purpose of the Study:

  • To systematically review the efficacy and safety of intravitreal complement inhibitors for GA in AMD.
  • To analyze treatment outcomes and adverse events associated with these therapies.

Main Methods:

  • A systematic literature search was conducted on PubMed and Web of Science.
  • 18 studies with 4272 patients were included, with a mean follow-up of 68.2 weeks.
  • Data on visual function, GA area change, and side effects were analyzed.

Main Results:

  • No significant difference in visual function change was observed between treated and control groups.
  • A statistically significant, albeit small, reduction in GA area progression was noted in treated patients (2.4 mm² vs. 2.7 mm²).
  • Ocular and systemic side effects were comparable to anti-VEGF treatments, with a noted incidence of choroidal neovascularization (CNV).

Conclusions:

  • Intravitreal complement inhibitors may offer a therapeutic option for GA in AMD.
  • Personalized patient selection is crucial for optimizing treatment outcomes.
  • Further research into CNV development is warranted.